Acute Stroke Clinical Trial
Official title:
A Pilot Study Assessing the Safety and Feasibility of Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke
Verified date | December 2017 |
Source | Capital Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Currently, early reperfusion is considered as the most effective therapy for the treatment of
acute ischemic stroke (AIS). Over the past 20 years, intravenous tissue plasminogen activator
(IV tPA) has been demonstrated to be the only effective therapy for AIS. More recently,
several large randomized clinical trials have concluded the superiority of endovascular
mechanical thrombectomy for AIS. Furthermore, with the development of materials and
techniques, the occluded artery can be recanalized with high percentage (60%-90%), and the
rate of recanalization is still being improved. A great number of AIS patients are now
eligible for revascularization therapy and there should be a good prognosis of AIS after
recanalizing the occluded artery using mechanical thrombectomy. However, things are never as
simple as wished to be. The rate of patients with functional independence is less than 50%
and over 15% patients died at 3 months post thrombectomy. The discrepancy between the
functional outcome and recanalization rates encourage researchers to explore strategies that
further improving the functional outcome of AIS patients.
Remote ischemic conditioning has been demonstrated to reduce cerebral infarct size in mouse
model of focal cerebral ischemia. And clinical researches demonstrated the protective effects
of remote ischemic conditioning in AIS patient treated with IV tPA,. However, whether remote
ischemic conditioning is safe and effective in protecting patients with large-vessel ischemic
stroke and undergoing endovascular treatment is still unknown.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 20, 2017 |
Est. primary completion date | September 17, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Acute ischemic stroke where patient is ineligible for intravenous thrombolytic treatment or the treatment is contraindicated, or where patient has received intravenous thrombolytic therapy without recanalization; 2. No remarkable pre-stroke functional disability (mRS = 1); 3. Age =18 and = 80; 4. Patient treatable within six hours of symptom onset; 5. Informed consent obtained from patient or acceptable patient's surrogate Exclusion Criteria: 1. Identified hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0; 2. Baseline platelet count < 30*109/L; 3. Baseline blood glucose of < 2.7mmol/L or >22.2mmol/L; 4. Renal insufficiency with creatinine = 265 umol/L; 5. Severe, sustained hypertension (SBP > 185 mmHg or DBP > 110 mmHg); 6. Woman of childbearing potential who is known to be pregnant or lactating; 7. Subject participating in a study involving other drug or device trial study; 8. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations; 9. Unlikely to be available for 90-day follow-up; 10. Contraindication for remote ischemic conditioning: severe soft tissue injury, fracture, or peripheral vascular disease in the upper limbs; 11. Hypodensity on CT or restricted diffusion amounting to an ASPECTS score of <7 on noncontrast CT; 12. CT or MRI evidence of hemorrhage; 13. Significant mass effect with midline shift on CT or MRI scans; 14. Subjects with artery occlusions in multiple vascular territories; 15. Evidence of intracranial tumor. |
Country | Name | City | State |
---|---|---|---|
China | Xuanwu Hospital, Capital Medical University | Beijing |
Lead Sponsor | Collaborator |
---|---|
Capital Medical University |
China,
Hausenloy DJ, Barrabes JA, Bøtker HE, Davidson SM, Di Lisa F, Downey J, Engstrom T, Ferdinandy P, Carbrera-Fuentes HA, Heusch G, Ibanez B, Iliodromitis EK, Inserte J, Jennings R, Kalia N, Kharbanda R, Lecour S, Marber M, Miura T, Ovize M, Perez-Pinzon MA, Piper HM, Przyklenk K, Schmidt MR, Redington A, Ruiz-Meana M, Vilahur G, Vinten-Johansen J, Yellon DM, Garcia-Dorado D. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016 Nov;111(6):70. Epub 2016 Oct 20. Review. — View Citation
Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, Li G, Ren C, Luo Y, Ling F, Jia J, Hua Y, Wang X, Ding Y, Lo EH, Ji X. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012 Oct 30;79(18):1853-61. doi: 10.1212/WNL.0b013e318271f76a. Epub 2012 Oct 3. — View Citation
Ren C, Wang P, Wang B, Li N, Li W, Zhang C, Jin K, Ji X. Limb remote ischemic per-conditioning in combination with post-conditioning reduces brain damage and promotes neuroglobin expression in the rat brain after ischemic stroke. Restor Neurol Neurosci. 2015;33(3):369-79. doi: 10.3233/RNN-140413. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with any RIC-related adverse events. | For all participants, adverse events will be assessed by as assessed by CTCAE v4.0. | 0-90 days after endovascular treatment. | |
Secondary | Change in cerebral artery blood flow velocity | Cerebral artery blood flow velocity is recorded continuously by Transcranial Doppler (TCD) during remote ischemic conditioning. | 0-7 days. | |
Secondary | Change in vital signs | Vital signs are documented continuously during remote ischemic conditioning. | 0-7 days. | |
Secondary | Change in intracranial pressure | Intracranial pressure is monitored by noninvasive intracranial pressure monitoring equipment during remote ischemic conditioning | 0-7 days. | |
Secondary | Change in plasma biomarkers | Plasma biomarkers include biochemical biomarkers (e.g.,creatine kinase), blood routine test and coagulation function (e.g., PT, APTT, TT). | 0-7 days. | |
Secondary | Final cerebral infarct volume. | The final infarct volume of cerebral infarct is evaluated by cranial noncontrast CT. | 5-9 days after endovascular treatment. | |
Secondary | Number of subjects completing all the designed RIC procedures. | 9 times (36 cycles) of RIC interventions are planned to be applied to each subject pre and post-endovascular treatment for 7 consecutive days. | 0-7 days. | |
Secondary | The severity of global disability at 90 days, as assessed by modified Rankin scale (mRS). | The mRS is an ordinal, graded interval scale that assigns patients among 7 global disability levels, which ranging from 0 (no symptom) to 5 (severe disability) and 6 (death). | 0-90 days. | |
Secondary | Symptomatic Intracerebral Hemorrhage. | Deterioration in NIHSS score of =4 points within 24 hours from treatment and evidence of hemorrhage in imaging scans. | 0-90 days. | |
Secondary | Any adverse event. | Adverse events related or not related to remote ischemic conditioning will be documented. | 0-90 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Enrolling by invitation |
NCT06074081 -
Comparison of 4-weeks of Motor Relearning Program and Mirror Therapy in Improving Upper Limb Motor Function in Stroke Patients.
|
N/A | |
Terminated |
NCT04039178 -
Efficacy of EMF BCI Based Device on Acute Stroke
|
N/A | |
Completed |
NCT04521634 -
Glycaemic Variability in Acute Stroke
|
||
Completed |
NCT03477188 -
The Effects of Somatosensory and Vestibular Rehabilitation Additional Conventional Therapy on Balance in Patients With Acute Stroke.
|
N/A | |
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT02677415 -
Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment
|
N/A | |
Recruiting |
NCT01541163 -
Heart and Ischemic STrOke Relationship studY
|
N/A | |
Completed |
NCT01210729 -
Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke
|
Phase 2 | |
Recruiting |
NCT00785343 -
Study of Robot-assisted Arm Therapy for Acute Stroke Patients
|
Phase 1 | |
Completed |
NCT04779710 -
How Does Dysphagia Assessment in Acute Stroke Affect Pneumonia?
|
||
Active, not recruiting |
NCT03635749 -
Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis
|
Phase 3 | |
Recruiting |
NCT06149754 -
BraiN20® Monitoring in Acute Stroke Undergoing Thrombectomy
|
||
Recruiting |
NCT04491695 -
Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke
|
Phase 2/Phase 3 | |
Recruiting |
NCT04283760 -
Investigation of the Reliability and Validity of the Movement Imagination Questionnaire - Revised Second in Acute Stroke Patients
|
||
Recruiting |
NCT05454397 -
A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients
|
||
Completed |
NCT04488692 -
Early Functional Training in Acute Stroke Inpatient Ward
|
N/A | |
Recruiting |
NCT04214522 -
Reliability and Validity of the Kinesthetic and Visual Imagery Questionnaire in Acute Stroke Patients
|
||
Not yet recruiting |
NCT04157231 -
Essential Acute Stroke Care in Low Resource Settings: a Pilot studY
|
N/A | |
Recruiting |
NCT05469438 -
IMAS Optimization and Applicability in an Acute Stroke Setting.
|